Margaret E. Duncan

1.5k total citations
18 papers, 1.3k citations indexed

About

Margaret E. Duncan is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Margaret E. Duncan has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Margaret E. Duncan's work include Protease and Inhibitor Mechanisms (6 papers), Carcinogens and Genotoxicity Assessment (5 papers) and Peptidase Inhibition and Analysis (5 papers). Margaret E. Duncan is often cited by papers focused on Protease and Inhibitor Mechanisms (6 papers), Carcinogens and Genotoxicity Assessment (5 papers) and Peptidase Inhibition and Analysis (5 papers). Margaret E. Duncan collaborates with scholars based in United Kingdom, United States and Germany. Margaret E. Duncan's co-authors include John E. Fothergill, William T. Melvin, Graeme I. Murray, P. Brookes, Judith McKay, G I Murray, Jonathan P. Richardson, Nuala A. Booth, Sybil M. McAleese and Rainald Fischer and has published in prestigious journals such as Nature, Nature Medicine and European Journal of Biochemistry.

In The Last Decade

Margaret E. Duncan

18 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret E. Duncan United Kingdom 14 834 631 513 240 138 18 1.3k
B Davies United Kingdom 8 717 0.9× 615 1.0× 417 0.8× 223 0.9× 137 1.0× 10 1.2k
J P Witty United States 11 494 0.6× 430 0.7× 456 0.9× 179 0.7× 92 0.7× 11 1.0k
Shouichi Higashi Japan 24 519 0.6× 459 0.7× 541 1.1× 204 0.8× 272 2.0× 38 1.3k
Carter Van Waes United States 18 408 0.5× 647 1.0× 821 1.6× 122 0.5× 116 0.8× 28 1.5k
Daniel Lottaz Switzerland 18 384 0.5× 235 0.4× 437 0.9× 229 1.0× 53 0.4× 26 1.0k
V‐M Kosma Finland 14 228 0.3× 335 0.5× 616 1.2× 117 0.5× 56 0.4× 20 1.3k
Michael J. Niedbala United States 14 377 0.5× 262 0.4× 303 0.6× 146 0.6× 158 1.1× 16 917
Janet M. Longcroft United Kingdom 13 400 0.5× 445 0.7× 583 1.1× 165 0.7× 84 0.6× 14 1.4k
Éric Guérin France 27 491 0.6× 693 1.1× 811 1.6× 121 0.5× 48 0.3× 75 1.7k
Ryuji Maekawa Japan 19 347 0.4× 550 0.9× 386 0.8× 63 0.3× 90 0.7× 51 1.2k

Countries citing papers authored by Margaret E. Duncan

Since Specialization
Citations

This map shows the geographic impact of Margaret E. Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret E. Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret E. Duncan more than expected).

Fields of papers citing papers by Margaret E. Duncan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret E. Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret E. Duncan. The network helps show where Margaret E. Duncan may publish in the future.

Co-authorship network of co-authors of Margaret E. Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret E. Duncan. A scholar is included among the top collaborators of Margaret E. Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret E. Duncan. Margaret E. Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society. 20(8). 1144–1155. 13 indexed citations
2.
Sawicki, Gregory S., Michael W. Konstan, Edward F. McKone, et al.. (2022). Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulmonary Therapy. 8(4). 385–395. 3 indexed citations
3.
Schwarz, C., Sivagurunathan Sutharsan, Ralph Epaud, et al.. (2020). Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis. 20(2). 228–233. 18 indexed citations
4.
Duncan, Margaret E.. (2019). Characterization of Mechanisms of Antibiotic Resistance in Neisseria gonorrhoeae. Carolina Digital Repository (University of North Carolina at Chapel Hill). 1 indexed citations
5.
Duncan, Margaret E., Jonathan P. Richardson, G I Murray, William T. Melvin, & John E. Fothergill. (1998). Human matrix metalloproteinase‐9 : activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. European Journal of Biochemistry. 258(1). 37–43. 49 indexed citations
6.
Murray, Graeme I., et al.. (1998). Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. The Journal of Pathology. 185(3). 256–261. 252 indexed citations
7.
Murray, Graeme I., et al.. (1998). Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer. The Journal of Pathology. 185(3). 256–261. 24 indexed citations
8.
Murray, Graeme I., et al.. (1996). Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer. Nature Medicine. 2(4). 461–462. 388 indexed citations
9.
Duncan, Margaret E., et al.. (1996). Expression of matrix metalloproteinases in colorectal cancer. Biochemical Society Transactions. 24(2). 329S–329S. 2 indexed citations
10.
Murray, Graeme I., et al.. (1996). Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer. Nature Medicine. 2(4). 461–462. 297 indexed citations
11.
Duncan, Margaret E., Sybil M. McAleese, Nuala A. Booth, William T. Melvin, & John E. Fothergill. (1992). A simple enzyme-linked immunosorbent assay (ELISA) for the neuron-specific γ isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. Journal of Immunological Methods. 151(1-2). 227–236. 17 indexed citations
12.
13.
Duncan, Margaret E. & P. Brookes. (1974). Enzyme activities in extracts of 8-azaguanine-resistant mutants of cultured chinese hamster cells induced by the carcinogen, 7-bromomethylbenz[α]anthracene. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 26(1). 37–48. 18 indexed citations
14.
Duncan, Margaret E. & P. Brookes. (1973). The induction of azaguanine-resistant mutants in cultured Chinese hamster cells by reactive derivatives of carcinogenic hydrocarbons. Mutation Research/Environmental Mutagenesis and Related Subjects. 21(2). 107–118. 56 indexed citations
15.
Duncan, Margaret E. & P. Brookes. (1973). The induction of azaguanine-resistant mutants in cultured Chinese hamster cells by reactive derivatives of carcinogenic hydrocarbons.. PubMed. 21(2). 107–18. 67 indexed citations
16.
Duncan, Margaret E. & P. Brookes. (1972). Metabolism and macromolecular binding of dibenz(a,c)anthracene and dibenz(a,h)anthracene by mouse embryo cells in culture. International Journal of Cancer. 9(2). 349–352. 16 indexed citations
17.
Brookes, P. & Margaret E. Duncan. (1971). Carcinogenic Hydrocarbons and Human Cells in Culture. Nature. 234(5323). 40–43. 43 indexed citations
18.
Duncan, Margaret E. & P. Brookes. (1970). The relation of metabolism to macromolecular binding of the carcinogen benzo[a]pyrene, by mouse embryo cells in culture. International Journal of Cancer. 6(3). 496–505. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Davies Breakdown of academic impact, for papers by J P Witty Breakdown of academic impact, for papers by Shouichi Higashi Breakdown of academic impact, for papers by Carter Van Waes Breakdown of academic impact, for papers by Daniel Lottaz Breakdown of academic impact, for papers by V‐M Kosma Breakdown of academic impact, for papers by Michael J. Niedbala Breakdown of academic impact, for papers by Janet M. Longcroft Breakdown of academic impact, for papers by Éric Guérin Breakdown of academic impact, for papers by Ryuji Maekawa
Rankless by CCL
2026